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Abstract
In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the 
different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, 
new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline mul-
tigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
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Introduction
Identification of individuals and families with clinical cri-
teria for early referral to a specialized genetic counseling 
unit (GCU) has been the basis for preventive medicine in 
familial–hereditary susceptibility to colorectal cancer so 
far. Genetic counseling and risk reduction strategies have 
avoided many new cancer diagnoses and have helped these 
individuals understand and adapt to all the implications of 
genetic predisposition to colorectal cancer.
In the near future, somatic and germline multigene panel 
testing will be incorporated into the routine care of cancer, 
early from its diagnosis. Targeted therapies candidates will 
be identified through these predictive molecular profiles and C. Guillén-Ponce, E. L. Aras, I. Lorenzo-Lorenzo, T. M. Gómez, 
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at the same time all known and actionable hereditary colo-
rectal cancer syndromes will be screened as well.
The main hereditary colorectal cancer syndromes will be 
reviewed in this guideline with their main clinical, molecular 
features and their appropriate surveillance recommendations.
Materials and methods
A medical literature review was conducted in NCBI Pub-
Med/EMBASE databases on the topics of the guideline. 
Evidence level and strength of the recommendations were 
based on GRADE http://www.grade worki nggro up.org/ [1–3] 
(Table 1).
Lynch syndrome (OMIM 120435)
Lynch syndrome (LS) is an autosomal dominant inherited 
cancer predisposition disease. Its estimated general popu-
lation prevalence is 1 in 279 [4]. LS accounts for about 
3% of colorectal cancer (CRC) [5] and 2% of endometrial 
cancer (EC) cases [6]. CRC is the most common associ-
ated tumor, usually right-sided, poorly differentiated, with 
mucinous features or medullary growth pattern, abundant 
infiltrating lymphocytes, propensity for synchronous and/
or metachronic tumors [7], and a better prognosis in the 
non-metastatic setting [8, 9]. LS also predisposes to EC, 
small intestinal, urinary tract, pancreaticobiliary, gastric and 
ovarian tumors, and slightly to breast and prostate cancers 
[7, 10–12]. Muir–Torre syndrome is characterized by skin 
tumors (sebaceous neoplasms, keratoacanthomas) and Tur-
cot’s syndrome includes glial brain tumors [7, 10]. The age 
of onset is younger compared with sporadic counterparts: 
45–60 years old (years) for CRC and 50 years for EC [13].
Lynch syndrome is caused by pathogenic germline vari-
ants in the DNA mismatch repair (MMR) genes MLH1, 
MSH2, MSH6, or PMS2 (and in the non-MMR gene EpCAM, 
in which deletions induce epigenetic silencing of MSH2) 
[10, 14]. When a second “hit” of somatic mutation occurs, 
the MMR function fails leading to cancers with microsatel-
lite instability (MSI) and hypermutation phenotype. Defi-
cient MMR (dMMR) and MSI are not exclusive to the LS 
and are also likely in sporadic cancers caused by MLH1 
promoter hypermethylation [15] or double somatic MMR 
mutations [16].
The age-specific cumulative risk could depend on geno-
type and sex [12, 13, 17–19] (Table 2). MSH2 mutation car-
riers have a higher risk of extracolonic cancers [12]. EpCAM 
deletions close to the MSH2 promoter are associated with 
increased risk of EC [20]. MSH6 and PMS2 mutations have 
a lower penetrance [4], except for EC in MSH6 carriers, who 
also present with cancer at later ages [19, 21].
LS diagnosis
Universal strategy with molecular analyses in unselected 
CRC or EC adds diagnostic sensitivity for LS over clinical 
criteria, with a favorable cost-effectiveness profile [22–25]. 
This information has prognostic and therapeutic value for 
Table 1  Evidence levels and strength of recommendation
Evidence levels
 A: High. Randomized well-designed clinical trials/well-conducted 
meta-analysis. It is unlikely that future studies on the topic will 
modify confidence in the outcome
 B: Moderate. Non-randomized prospective studies. It is likely 
that future studies on the topic will modify the confidence in the 
estimated outcome
 C: Low or very low. Observational studies. Future studies on the 
topic will very likely change not only the confidence in the out-
come but the outcome itself
Strength of recommendation
 1. Strong recommendation on the measure/intervention we are 
considering: advantages of the intervention outweigh the risks and 
also are cost-efficient
 2. Weak recommendation: advantages and disadvantages are not far 
from each other
Table 2  Lifetime cancer risks related to LS genotype and sex
CNS central nervous system, CRC colorectal cancer, EC endometrial cancer
Cancer site MLH1 male MLH1 female MSH2 male MSH2 female MSH6 male MSH6 female PMS2 male PMS2 female
Any LS cancer 59% 80% 71% 75% 31% 71%
CRC 34–47% 36–45% 37–47% 33–37% 14–22% 10–26% 13–20% 11–15%
EC 42.7% 56.7% 46.2% 13–24%
Ovarian 10.1% 16.9% 13.1%
Urinary tract 1.2% 3% 8% 10% 0.7%
Gastric 20% 8% 2% 9%
Small bowel 0.4% 1.1%
Biliary/pancreatic 1.9% 0.02%
CNS gliomas 1.0% 5.3% 1.4%
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common clinical practice. Multigene NGS in CRC, includ-
ing MMR and BRAF genes, with computational tools for 
MSI testing, has a higher diagnostic sensitivity compared 
with a universal strategy based on immunohistochemis-
try (IHC) and BRAF analyses (100% sensitivity [95% CI 
93.8–100] versus 89.7%, [95% CI 78.8–96.1], p = 0.04) 
[26]. In a prospective study of > 15.000 unselected cancer 
patients with 50 different histologies, a similar NGS device 
increased LS diagnostic sensitivity over revised Bethesda 
Criteria (rBC) plus universal strategy [27]. Somatic NGS 
panels are available in clinical practice for precision oncol-
ogy due to their predictive value. Direct germline multigene 
NGS in unselected patients with CRC increases diagnostic 
sensitivity for less prevalent hereditary syndromes more than 
for LS [5, 28] (Fig. 1). When there are no tumor samples, 
fulfillment of rBC or a ≥ 2.5% likelihood of LS on the vali-
dated  PREMM5 prediction model [29] can be used for refer-
ral to a GCU. Although NGS is continuously less expensive, 
cost-effectiveness studies for LS diagnostic strategies that 
incorporate these platforms are lacking.
Recommendation Different screening strategies for LS of 
all newly diagnosed CRC and EC can be considered includ-
ing tumor tests for defective MMR function and/or high-
level MSI and/or NGS tumor sequencing including BRAF.
In case of lack of expression of MLH1 and PMS2 by 
immunohistochemistry, BRAFV600E mutation and/or 
MLH1 promoter hypermethylation should be carried out to 
rule out sporadic cases.
Patients with molecular profiles compatible with LS 
should be referred to GCU for appropriate counseling and 
NGS germline genetic testing.
In families with fulfillment of rBC or a ≥ 2.5% likelihood 
of LS on the  PREMM5 prediction model, prevalent and/or 
previous CRC and/or EC should follow the same screen-
ing procedure before considering referral to GCU (evidence 
level B, strength 1).
               Diagnosis of Endometrial Cancer                           Diagnosis of Colorectal Cancer                         Precision Oncology in Metastatic Cancer
                                                                                                                                                                                                                                                                     Alternative                          Opportunistic
                                        Tumor testing for DMMR (by IHC)                                                                                            Tumor NGS including BRAF         screening
                                                       or for MSI (by PCR)                                                                                                                                        and computational tools for MSI 
                          Intact proteins                   High MSI                                 Abnormal IHC                                   No mutation                 No mutation                Mutation                Mutation     
                             or low MSI                                                                                                                                                              high MSI‡                       low MSI                  positive                   positive
                  HCP genes        non-HCP genes
                        Sporadic cancer                     Likely sporadic cancer                                    high MSI.
                      Loss of MLH1 and PMS2        Loss of MSH2 or MSH6 (or both) or PMS2                                                                                                              Consider‡
           BRAF V600E mutation (for colorectal cancer)                                                                                                                          Genetic Counseling Unit
                  and/or MLH1 methylation status*
              Germline genetic testing: consider multigene-NGS
BRAF positive         BRAF negative and/or                  BRAF negative and/or
MLH1 methylation positive             MLH1 methylation negative                      Positive for MMR                                Positive for other                                        Negative
                       gene mutation                                       HCP genes                          
    Consider germline MLH1 methylation                   Tumor NGS/review previous
and germline MLH1 gene at Genetic Counseling Unit                       
citamoSnoitatumoNcitamoselgnis/elbuoDevitisoPevitageN
                       MMR gene mutation                                 mutations in
                       (if MLH1, consider*)  non-MMR genes
    Sporadic cancer                                                                                                                       Lynch Syndrome                         Other HCP Syndromes   Sporadic cancer    High MSI: LLS      Possible SSA
Fig. 1  Lynch Syndrome diagnostics. HCP hereditary cancer predisposition, LLS Lynch-like syndrome, MMR mismatch repair, MSI microsatel-
lite instability, NGS next-generation sequencing, SSA secondary somatic alterations
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Management of LS: cancer prevention
Screening and surgical management for CRC prevention
Prospective data with long-term follow-up demonstrate that 
early colonoscopy repeated frequently in LS carriers signifi-
cantly reduces CRC incidence, CRC associated mortality, 
and overall mortality [30].
Recommendation Colonoscopies should be performed 
every 1–2 years for healthy individuals with LS, beginning 
at 20–25 years or 2–5 years before the youngest age at which 
CRC was diagnosed in the family if this occurred before 
25 years (evidence level B, strength 1).
Risk of metachronous CRC is up to 62% at 30-year fol-
low-up among patients with LS and segmental resection 
of the primary tumor [31]. In a meta-analysis of 6 studies 
(mean 9-year follow-up), rates of metachronous CRC were 
reduced by 3.4 times with subtotal colectomy, although a 
survival benefit was not found [32].
Recommendation Extended colonic resection may be an 
option for young patients with CRC, severe LS phenotype, 
good bowel function, no comorbidities, and compliance 
with endoscopic surveillance after surgery (evidence level 
A, strength 1).
Risk‑reducing surgery for EC and ovarian cancer (OC)
Observational data have shown that hysterectomy and sal-
pingo-oophorectomy have efficacy for prevention of EC and 
OC in women with LS, although it remains unclear whether 
surgery confers any survival benefit [33]. Psychological, 
cardiovascular, endocrinologic, skeletal, and sexual conse-
quences of early onset menopause, and the risk burden asso-
ciated with specific genes must be kept in mind to discuss 
the optimal timing of risk-reducing surgery.
Recommendation Risk-reducing hysterectomy and sal-
pingo-oophorectomy at the completion of childbearing and/
or since the early 40s (evidence level C, strength 1) should 
be considered.
Chemotherapeutic prevention
A long-term analysis in CAPP2 study demonstrated a 
marked reduction in CRC incidence (incidence rate ratio 
[IRR], 0.37 [95% CI 0.18–0.78], p = 0.008) and in any LS-
associated cancer (IRR, 0.42 [95% CI 0.25–0.72], p = 0.001) 
among LS carriers who took aspirin at dose of 600 mg/day 
for 2 or more years compared with those randomly assigned 
to placebo [34].
Recommendation Daily aspirin can be considered for LS 
cancer prevention, although the ideal dose and duration of 
use are as yet undefined (evidence level A, strength 2).
Management of LS: specific issues on cancer 
treatment
Adjuvant chemotherapy with 5-fluorouracil did not result in 
a survival benefit in subgroup analyses of patients with stage 
II colon cancer with dMMR [35].
In patients with dMMR metastatic CRC and previous cyto-
toxic agents failure, anti-programmed death 1 (PD-1) antibody 
nivolumab resulted in objective response rate (ORR) of 31.1% 
(95% CI 20.8–42.9) (median follow-up time, 12.0 months) 
[36]. In the same setting, the combination of nivolumab plus 
ipilimumab (anti-cytotoxic T-lymphocyte antigen 4 anti-
body) reached an ORR of 55% (95% CI 45.2–63.8) (median 
follow-up time, 13.4 months), with progression-free survival 
and overall survival rates at 12 months of 71% and 85%, 
respectively, and a manageable treatment-related grade 3–4 
toxicity in 32% of patients [37]. In dMMR cancers across 12 
different histologies, ORR of 53% (95% CI 42–64) and com-
plete responses in 21% of patients (median follow-up time, 
12.5 months) were observed with anti-PD-1 antibody pem-
brolizumab [38].
Recommendation Adjuvant chemotherapy is not indicated 
in stage II LS-associated colon cancer (evidence level B, 
strength 1). Different immunotherapy options are valid for 
pretreated recurrent or metastatic LS-associated cancers 
(evidence level B, strength 1).
Familial adenomatous polyposis
Familial adenomatous polyposis (FAP) was first associ-
ated with mutations in the APC, and later in the MUTYH. 
Additional genes such as POLE, POLD1, NTHL1, MSH3, 
GREM1 have been recently associated. Extracolonic mani-
festations may be present and help with the clinical diagno-
sis (Table 3).
APC‑associated polyposis, FAP or AAP (OMIM 
175100) [39, 40]
It is an autosomal dominant inherited disease caused by 
germline mutations (> 85% point mutations, 10–15% large 
rearrangements) in APC which encodes a protein with a sig-
nificant role in the Wnt-β-catenin signaling. Up to 30% of 
carriers are due to de novo mutations or to somatic mosai-
cism. There are genotype–phenotype correlations. The 
clinical presentations are: (a) classic FAP, ≥ 100 polyps, 
appearing between 10 and 30 years, first located in rectum 
and sigma afterwards along the colon and development of 
CRC in almost 100% if untreated, at a mean age of 39 years. 
(b) Attenuated FAP (AFAP), < 100 polyps located in proxi-
mal colon and lesser risk of CRC, 70%, at a mean age of 
50–55 years. (c) Gastric adenocarcinoma and proximal poly-
posis of the stomach (GAPP), none or few polyps in colon.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































207Clinical and Translational Oncology (2020) 22:201–212 
1 3
MUTYH‑associated polyposis, MAP (OMIM 608456) 
[39, 41]
It is an autosomal recessive disease caused by bi-allelic, 
homozygous or compound heterozygous, germline muta-
tions (> 99% point mutations, < 1% large rearrangement) in 
MUTYH which encodes a glycosylase of DNA base excision 
repair system. Somatic G:C to T:A transversions result in 
genes implicated in CRC carcinogenesis, such as APC or 
KRAS. The most frequent phenotype is AFAP, at a mean 
age of 45 years, but maybe classic FAP, serrated polyposis 
and few individuals develop CRC without polyposis. Geno-
type–phenotype correlation has been described. The risk of 
CRC is 43–100% at the age of 50 years.
For the study of FAP, single gene testing has been the 
traditional approach, but the use of a multigene panel should 
be specially considered in attenuated FAP.
Recommendation Criteria for referral to a GCU and 
APC/MUTYH or multigene panel testing (evidence level B, 
strength 1):
1. Patients with > 10 synchronous adenomatous colonic 
polyps histologically confirmed.
2. Family history of adenomatous colonic polyps (> 10 
in > 1 relative), at young age and extracolonic manifes-
tations.
3. Gastric polyps (> 100), in body and fundus, preponder-
antly fundic glands polyps. Proton pump inhibitor use 
must be excluded.
4. Consider in: hepatoblastoma, desmoid tumor, cribri-
form-morular variant of papillary thyroid carcinoma, 
multifocal or bilateral congenital hypertrophy of retinal 
pigmented epithelium.
5. Known familial mutation in at-risk relatives.
Colorectal surveillance
In classical FAP, flexible sigmoidoscopy or colonoscopy 
should be carried out every 1–2  years, starting at age 
12–15 years. If adenomas are found at sigmoidoscopy, 
then it should be annual colonoscopy [43]. In AFAP, colo-
noscopy should be performed every 1–2 years starting at 
age 18–20 years and surgery is indicated if there is a high 
number of adenomas. In MAP, colonoscopy should be per-
formed every 1–2 years, starting at 18–20 years and if polyps 
cannot be controlled endoscopically, colectomy should be 
considered [43, 44]. For MUTYH heterozygote, colonos-
copy should be performed every 5 years, beginning at age 
40 years or 10 years prior to age of first-degree relative’s age 
at CRC diagnosis [42, 44].
Recommendation Surgery is indicated if there is a high 
number of adenomas or a high degree of dysplasia (evidence 
level B, strength 1).
Surgical options of colon and rectum
Surgical options in FAP patients are total abdominal colec-
tomy with ileorectal anastomosis (TAC/IRA) or total proc-
tocolectomy with pouch anal anastomosis (TPC/IPAA) 
[42–44]. Surveillance of rectum depends on the type of 
surgery [42, 43].
Recommendation TPC/IPAA or TAC/IRA should be 
carried out depending on age, severity of rectal polypo-
sis and risk of developing desmoids. In FAP, it is usually 
recommended in the 2nd decade of life (evidence level 
B, strength 1). IPAA is generally recommended for FAP, 
and IRA for AFAP and MAP. Afterwards, surveillance 
of the rectum should be carried out every 6–12 months 
if rectal tissue remains, and every 1–3 years if ileoanal 
pouch is present, depending on polyp burden (evidence 
level B, strength 1).
Extracolonic manifestations
For gastroduodenal adenomas, upper endoscopy (including 
complete visualization of the ampulla of Vater) should be 
performed starting at 25–30 years or at the time of diag-
nosis of colonic polyposis [43]. Surveillance intervals are 
based on the Spigelman’s stage of duodenal polyposis: 0 
(no polyposis): 4 years; I (1–4 tubular adenomas, 1–4 mm): 
2–3 years; II (5–19 tubular adenomas, 5–9 mm): 1–3 years; 
III (≥ 20, ≥ 1 cm): 6–12 months; and IV (dense polyposis or 
high grade): surgery [42, 44]. Duodenal adenomas are man-
aged by endoscopic polypectomy, although duodenectomy 
or duodenal pancreatectomy may be necessary in advanced 
cases [43].
Patients with classical FAP have a lifetime thyroid cancer 
risk of 2–6% and annual surveillance is recommended [42, 
44].
Treatments for desmoid tumors are surgery, non-steroid 
anti-inflammatory drugs (NSAIDs), anti-oestrogen agents, 
chemotherapy, imatinib, sorafenib, pazopanib and radio-
therapy [44].
The absolute risk for hepatoblastoma in FAP is estimated 
at less than 2% and it occurs prior to the age of 3 years [42].
Recommendation Surveillance of duodenal adeno-
mas is based on the Spigelman’s stage (evidence level B, 
strength 1). In MAP, upper endoscopy is recommended at 
30–35 years (evidence level C, grade 2). For thyroid can-
cer, annual thyroid examination and thyroid ultrasound 
should start at 25–30 years (evidence level C, strength 2). 
For desmoid tumors, annual abdominal palpation and mag-
netic resonancy (MRI) or computer tomography (CT) scan 
should be done within 1–3 years post-colectomy and then 
every 5–10 years (evidence level C, strength 2); also surgery 
should be reserved for small, well-defined tumors, and if a 
208 Clinical and Translational Oncology (2020) 22:201–212
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clear margin can be obtained (evidence level B, strength 
2). For hepatoblastoma, consider liver palpation, abdominal 
ultrasound and alpha-fetoprotein (AFP) measurement every 
3–6 months before 5 years (evidence level C, strength 2).
Chemoprevention
The use of NSAIDs (sulindac or celecoxib) has been shown 
to reduce the number and extent of CRC and duodenal ade-
nomas, but without the clinical benefit of decrease in cancer 
risk [42, 43]. Due to the cardiovascular risk of NSAIDs, no 
drug has been approved.
Recommendation The use of NSAIDs to prevent CRC 
and duodenal adenomas needs to be balanced with the side 
effects (evidence level A, strength 2).
Hamartomatous polyposis and other 
non‑adenomatous polyposis
There are several classifications for hereditary syndromes 
with polyposis; one of the most accepted distributes them 
into four large groups: adenomatous, hamartomatous, ser-
rated and mixed polyposis [45].
These PS are very rare with the exception of serrated poly-
posis syndrome (SPS); the estimated incidence for PTEN 
hamartoma tumor syndrome is 1 in 200,000–250,000; for 
Peutz–Jeghers syndrome it is 1 in 250,000; for juvenile polyposis 
syndrome it is from 1 to 1.6 in 100,000. The SPS prevalence is 
higher than for other PS, including FAP; overall, its seems lower 
than 0.09–42 in 10,000 in colonoscopy-based CRC screening 
programs, but it is considerably higher in positive fecal occult 
blood test populations, with estimates of 0.34–0.66% or 31–80 
in 10,000 [46–51]. Sessile serrated polyposis cancer syndrome 
(SSPCS) is a very rare disorder caused by heterozygous muta-
tion in the RNF43 gene [49]. While most SPS cases are sporadic, 
evidence suggests that this syndrome exhibits a genetic compo-
nent at least occasionally. The higher prevalence of CRC and 
serrated polyps in first-degree relatives (FDRs) as compared to 
the general population supports this theory.
Table 3 summarizes the main characteristics and rec-
ommendations of surveillance of Adenomatous polyposis, 
Hamartomatous polyposis and Non-adenomatous PS accord-
ing to recommendations of the European Society of Gastro-
intestinal Endoscopy (ESGE) Guideline [46] or, in the rest 
of the cases, suggested by other referenced authors.
Multigene panel testing in familial CRC 
The introduction of NGS technologies for the genetic diag-
nosis of hereditary cancer predisposition syndromes repre-
sents a surpassing progress in the knowledge of this field. 
Multigene panel testing allows the simultaneous analysis 
Table 4  Refering to clinical genetics for CRC 
a Lynch syndrome-related cancers: colorectal, endometrial, gastric, ovarian, pancreatic, ureter and renal pelvis, brain, small intestinal cancer and 
sebaceous adenoma, sebaceous carcinoma, keratoacanthoma
b APC-associated polyposis conditions: familial adenomatous polyposis, attenuated familial adenomatous polyposis
c PTEN hamartoma tumor syndrome: Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome, PTEN-related proteus syndrome, proteus-like 
syndrome





Colorectal or endometrial cancer diagnosed < 50 years
Colorectal or endometrial cancer and another synchronous or metachro-
nous Lynch syndrome-related  cancersa
Colorectal or endometrial cancer and ≥ 1 first–second-degree relative 
(FSDR) with Lynch syndrome-related  cancersa
Family history of ≥ 1 first-degree relative (FDR) with colorectal or endo-
metrial cancer diagnosed < 50 years
Family history of ≥ 2 FDR or FSDR with Lynch syndrome-related 
 cancera regardless of age at diagnosis
Colorectal or endometrial cancer at any age showing evidence of mis-
match repair deficiency (MMR), either by microsatellite instability or 
loss of MMR protein expression
Lynch syndrome C 1
> 10 adenomatous polyps APC-associated polyposis  conditionsb
MUTYH-associated polyposis
C 1
≥ 2 hamartomatous polyps Peutz–Jeghers syndrome
PTEN hamartoma tumor  syndromec
Juvenile poliposis syndrome
C 1
≥ 5 serrated polyps proximal to the sigmoid colon Serrated polyposis syndrome C 1
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of multiple genes by NGS increasing the diagnostic yield, 
reducing the response times in a cost-effective manner, when 
compared to iterative single gene or phenotype-driven test-
ing [52]. On the other hand, there is a higher chance of iden-
tifying variants of uncertain significance that are not action-
able, or variants for which clinical management is uncertain 
such as finding a pathogenic variant in a moderate risk gene 
[53].
There is a high variability in the genes included across 
the multigene panels for CRC. Although a batch of genes 
considered clinically actionable with quantified magnitude 
of risk are present in virtually all panels, there is a signifi-
cant amount of genes that lack comprehensive validation or 
have less evidence of association with CRC/polyposis and 
consequently minimal clinical utility, that are included in 
many multigene panels. In fact, recent data from the ClinGen 
Clinical Validity framework show that < 60% of the genes on 
clinically available panels have strong or definitive evidence 
of association with hereditary colorectal cancer or polyposis, 
and > 40% have only moderate, limited, disputed, or refuted 
evidence [54].
The current lack of consensus regarding inclusion of 
genes in CRC panels represents a challenge in patient coun-
seling and management (Table 4). There is an urgent need 
to provide consensus on the genes included in multigene 
panels. This consensus should be based on structured assess-
ment of the clinical relevance of the genes, with standard-
ized reporting and clinical management guidelines [55].
For the current guidelines, we have reviewed the available 
information from reputable sources with expert panels to 
define strength of evidence and evaluate the clinical utility 
of genes associated with CRC and polyposis. Therefore, we 
considered the following sources: (i) the NCCN Guidelines 
for colorectal cancer v1.2019 [53], (ii) ClinGen Clinical 
Validity framework [54] and (iii) Lorans et al.’s review [55]. 
The applied criteria to evaluate the level of validation are 
slightly different among them with some discordant results. 
In Table 5, the list of genes considered to have strong higher-
ranking evidences for their association to hereditary forms 
of CRC/polyposis in at least one of the considered sources 
is shown. The total number of included genes is 18. Eleven 
genes have fully concordant classification among the three 
sources: APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, 
MUTYH, PMS2, PTEN, SMAD4 and STK11, while seven 
genes show discordant classification: AXIN2, BLM, GREM1, 
NTHL1, POLD1, POLE and TP53. Multigene panel testing 
for hereditary CRC and polyposis is a rapidly evolving land-
scape. A periodical review and consequent actualization of 
panels, if necessary, is recommended.
Recommendation Multigene panel testing for hereditary 
CRC and polyposis should include the genes:
– APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, 
MUTYH, PMS2, PTEN, SMAD4 and STK11 (evidence 
level A, strength 1).
– AXIN2, BLM, GREM1, NTHL1, POLD1, POLE and 
TP53 (evidence level B, strength 2).
Compliance with ethical standards 
Conflict of interest CGP reports congress registration  and accom-
modation from Sanofi. ELA has nothing to disclose. ILL has nothing 
to disclose. TMG reports congress registration and accommodation 
from Roche. RMCH reports consultant or advisory role from Servier, 
Celgene, Sanofi, Innoup Farma; speaker for Sanofi, Rovi, Hoffmann-
Roche, Servier, Nutricia Oncology, Bristol-Myers Squibb, AstraZen-
eca, Pfizer, Takeda, Ipsen Pharma, Merck Sharp and Dohme, Bayer 
Hispania and PharmaMar; Travel and Accommodation from Eli Lilly 
and Company and Kyowa Kirin. ABSH reports a consultant or advi-
sory role from Tesaro; honoraria for being a speaker for Roche and 
AstraZeneca and travel and congress assistance from MSD. RSB has 
nothing to disclose. CSR has nothing to disclose. JLS has nothing to 
disclose. LR reports congress registration from Roche and Servier and 
honoraria for being a speaker for Astrazeneca.
Ethical standards This guideline has been performed in accordance 
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
Informed consent There is not an informed consent statement for the 
elaboration of this guideline.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, 
Alonso-Coello P, et al. GRADE: an emerging consensus on rat-
ing quality of evidence and strength of recommendations. BMJ. 
2008;336(7650):924–6.
 2. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, 
Schünemann HJ. What is “quality of evidence” and why is it 
important to clinicians? BMJ. 2008;336(7651):995–8.
 3. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Lib-
erati A, et al. Going from evidence to recommendations. BMJ. 
2008;336(7652):1049–51.
 4. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles 
GG, et  al. Prevalence and penetrance of major genes and 
211Clinical and Translational Oncology (2020) 22:201–212 
1 3
polygenes for colorectal cancer. Cancer Epidemiol Biomark 
Prev. 2017;26(3):404–12.
 5. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick 
JL, et al. Cancer susceptibility gene mutations in individuals 
with colorectal cancer. J Clin Oncol. 2017;35(10):1086–95.
 6. Watkins JC, Yang EJ, Muto MG, Feltmate CM, Berkowitz RS, 
Horowitz NS, et al. Universal screening for mismatch-repair 
deficiency in endometrial cancers to identify patients with 
Lynch syndrome and Lynch-like Syndrome. Int J Gynecol 
Pathol. 2017;36(2):115–27.
 7. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. 
Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 
2015;15(3):181–94.
 8. Popat S, Houlston RS. A systematic review and meta-anal-
ysis of the relationship between chromosome 18q genotype, 
DCC status and colorectal cancer prognosis. Eur J Cancer. 
2005;41(14):2060–70.
 9. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, 
et al. Role of deficient DNA mismatch repair status in patients 
with stage III colon cancer treated with FOLFOX adjuvant 
chemotherapy: a pooled analysis from 2 randomized clinical 
trials. JAMA Oncol. 2018;4(3):379–83.
 10. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, 
Burt RW. AGC clinical guideline: genetic testing and manage-
ment of hereditary gastrointestinal cancer syndromes. Am J 
Gastroenterol. 2015;110(2):223–63.
 11. Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, 
Järvinen HJ, et al. The risk of extra-colonic, extra-endometrial 
cancer in the Lynch syndrome. Int J Cancer. 2008;123(2):444–9.
 12. Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, 
Evans DG, et al. Cancer risk and survival in path_MMR carriers 
by gene and gender up to 75 years of age: a report from the Pro-
spective Lynch Syndrome Database. Gut. 2018;67(7):1306–16.
 13. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, 
Evans DG, et al. Cancer incidence and survival in Lynch syn-
drome patients receiving colonoscopic and gynaecological 
surveillance: first report from the prospective Lynch syndrome 
database. Gut. 2017;66(3):464–72.
 14. Boland CR, Lynch HT. The history of Lynch syndrome. Fam 
Cancer. 2013;12(2):145–57.
 15. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibo-
deau SN, Lindor N, et al. Molecular characterization of MSI-H 
colorectal cancer by MLHI promoter methylation, immunohis-
tochemistry, and mismatch repair germline mutation screening. 
Cancer Epidemiol Biomark Prev. 2008;17(11):3208–15.
 16. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman 
R, de la Chapelle A, et al. Colon and endometrial cancers with 
mismatch repair deficiency can arise from somatic, rather than 
germline, mutations. Gastroenterology. 2014;147(6):1308–16.
 17. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bern-
stein I, Buchanan DD, et al. Cancer risks for PMS2-associated 
Lynch syndrome. J Clin Oncol. 2018;36(29):2961–8.
 18. Win AK, Lindor NM. Lynch syndrome (hereditary nonpolyposis 
colorectal cancer): clinical manifestations and diagnosis. Upto-
date.com. 2019.
 19. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, 
Longy M, et al. Cancer risks associated with germ-line muta-
tions in MLH1, MSH2, and MSH6 genes in Lynch syndrome. 
JAMA. 2011;305(22):2304–10.
 20. Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter 
P, Rahner N, et al. Risk of colorectal and endometrial cancers 
in EPCAM deletion-positive Lynch syndrome: a cohort study. 
Lancet Oncol. 2011;12(1):49–55.
 21. Baglietto L, Lindor NM, Dowty JG, White DM, Wag-
ner A, Gómez García EB, et  al. Risks of Lynch syndrome 
cancers for MSH6 mutation carriers. J Natl Cancer Inst. 
2010;102(3):193–201.
 22. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, 
Aaltonen LA, et al. Identification of Lynch syndrome among 
patients with colorectal cancer. JAMA. 2012;308(15):1555–65.
 23. Leenen CH, Goverde A, de Bekker-Grob EW, Wagner A, van Lier 
MG, Spaander MC, et al. Cost-effectiveness of routine screening 
for Lynch syndrome in colorectal cancer patients up to 70 years 
of age. Genet Med. 2016;18(10):966–73.
 24. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, 
Ferguson K, et al. Tumor mismatch repair immunohistochemistry 
and DNA MLH1 methylation testing of patients with endometrial 
cancer diagnosed at age younger than 60 years optimizes triage for 
population-level germline mismatch repair gene mutation testing. 
J Clin Oncol. 2014;32(2):90–100.
 25. Goverde A, Spaander MC, van Doorn HC, Dubbink HJ, van den 
Ouweland AM, Tops CM, et al. Cost-effectiveness of routine 
screening for Lynch syndrome in endometrial cancer patients up 
to 70 years of age. Gynecol Oncol. 2016;143(3):453–9.
 26. Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel 
WL, et al. Assessment of tumor sequencing as a replacement for 
Lynch syndrome screening and current molecular tests for patients 
with colorectal cancer. JAMA Oncol. 2018;4(6):806–13.
 27. Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Man-
delker D, et  al. Microsatellite instability is associated with 
the presence of Lynch syndrome pan-cancer. J Clin Oncol. 
2019;37(4):286–95.
 28. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller 
K, et al. Prevalence and spectrum of germline cancer suscepti-
bility gene mutations among patients with early-onset colorectal 
cancer. JAMA Oncol. 2017;3(4):464–71.
 29. Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurge-
lun MB, et al. Development and validation of the  PREMM5 model 
for comprehensive risk assessment of Lynch syndrome. J Clin 
Oncol. 2017;35(19):2165–72.
 30. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen 
LA, Peltomäki P, et al. Controlled 15-year trial on screening for 
colorectal cancer in families with hereditary nonpolyposis colo-
rectal cancer. Gastroenterology. 2000;118(5):829–34.
 31. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, 
et al. Metachronous colorectal cancer risk for mismatch repair 
gene mutation carriers: the advantage of more extensive colon 
surgery. Gut. 2011;60(7):950–7.
 32. Heneghan HM, Martin ST, Winter DC. Segmental vs extended 
colectomy in the management of hereditary nonpolyposis colo-
rectal cancer: a systematic review and meta-analysis. Colorectal 
Dis. 2015;17(5):382–9.
 33. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman 
PT, Clark MB, et al. Prophylactic surgery to reduce the risk of 
gynecologic cancers in the Lynch syndrome. N Engl J Med. 
2006;354(3):261–9.
 34. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Ols-
chwang S, et al. Long-term effect of aspirin on cancer risk in car-
riers of hereditary colorectal cancer: an analysis from the CAPP2 
randomised controlled trial. Lancet. 2011;378(9809):2081–7.
 35. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, 
Hamilton SR, et al. Defective mismatch repair as a predictive 
marker for lack of efficacy of fluorouracil based adjuvant therapy 
in colon cancer. J Clin Oncol. 2010;28(20):3219–26.
 36. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, 
Morse MA, et al. Nivolumab in patients with metastatic DNA 
mismatch repair-deficient or microsatellite instability-high colo-
rectal cancer (CheckMate 142): an open-label, multicentre, phase 
2 study. Lancet Oncol. 2017;18(9):1182–91.
 37. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino 
F, Aglietta M. Durable clinical benefit with nivolumab plus 
212 Clinical and Translational Oncology (2020) 22:201–212
1 3
ipilimumab in DNA mismatch repair-deficient/microsatel-
lite instability high metastatic colorectal cancer. J Clin Oncol. 
2018;36(8):773–9.
 38. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, 
et al. Mismatch repair deficiency predicts response of solid tumors 
to PD-1 blockade. Science. 2017;357(6349):409–13.
 39. Valle L. Recent discoveries in the genetics of familial colo-
rectal cancer and polyposis. Clin Gastroenterol Hepatol. 
2017;15:809–19.
 40. Nielsen M, Aretz S. Familial adenomatous polyposis or APC-
associated polyposis. In: Valle L, Gruber SB, Capellá G, editors. 
Hereditary colorectal cancer. Genetic basis and clinical impli-
cations. Cham: Springer International Publishing AG; 2018. p. 
99–112.
 41. Nielsen M, Aretz S. Adenomatous polyposis syndromes: 
MUTYH-associated polyposis. In: Valle L, Gruber SB, Capellá 
G, editors. Hereditary colorectal cancer. Genetic basis and clinical 
implications. Cham: Springer International Publishing AG; 2018. 
p. 135–48.
 42. Genetic/Familial High-Risk Assessment: Colorectal. NCCN Clini-
cal Practice Guidelines in Oncology. Version 2.2019. 2019. https 
://www.nccn.org/profe ssion als/physi cian_gls/pdf/genet ics_colon 
.pdf.
 43. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, 
Balmaña J, et al. Hereditary gastrointestinal cancers: ESMO Clini-
cal Practice Guidelines for diagnosis, treatment and follow-up. 
Ann Oncol. 2019;30:1558–71.
 44. Herzig D, Hardiman K, Weiser M, You N, Paquette I, Feingold 
DL, et al. The American Society of Colon and Rectal Surgeons 
clinical practice guidelines for the management of inherited poly-
posis syndromes. Dis Colon Rectum. 2017;60(9):881–94.
 45. Urioste Azcorra M. Aspectos moleculares de los síndromes 
polipósicos. In: Cáncer hereditario. 3ª Ed. © 2019. Sociedad Espa-
ñola de Oncología Médica (SEOM). ISBN: 978-84-09-10462-8.
 46. van Leerdam ME, Roos VH, van Hooft JE, Dekker E, Jover R, 
Kaminski MF, et al. Endoscopic management of polyposis syn-
dromes: European Society of Gastrointestinal Endoscopy (ESGE) 
guideline. Endoscopy. 2019;51(9):877–95.
 47. Larsen Haidle J, Howe JR. Juvenile polyposis syndrome. 2003 
May 13 [Updated 2017 Mar 9]. In: Adam MP, Ardinger HH, 
Pagon RA, et al., editors.  GeneReviews® [Internet]. Seattle: Uni-
versity of Washington, Seattle; 1993–2019. https ://www.ncbi.nlm.
nih.gov/books /.
 48. McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers syndrome. 2001 
Feb 23 [Updated 2016 Jul 14]. In: Adam MP, Ardinger HH, Pagon 
RA, et al., editors.  GeneReviews® [Internet]. Seattle: University of 
Washington, Seattle; 1993–2019. https ://www.ncbi.nlm.nih.gov/
books /.
 49. Pilarski R. PTEN Hamartoma tumor syndrome: a clinical over-
view. Cancers. 2019;11(6):844.
 50. OMIM: # 617108. Sessile serrated polyposis cancer syndrome; 
SSPCS. https ://www.omim.org/entry /61710 8?searc h=%23617 
108&highl ight=61710 8. Accessed 21 Aug 2019.
 51. Stanich PP, Pearlman R, Hinton A, Gutierrez S, LaDuca H, 
Hampel H, Jasperson K. Prevalence of germline mutations in 
polyposis and colorectal cancer-associated genes in patients 
with multiple colorectal polyps. Clin Gastroenterol Hepatol. 
2019;17(10):2008–15.
 52. Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola 
LM, Horike-Pyne M, et al. Next-generation sequencing panels 
for the diagnosis of colorectal cancer and polyposis syndromes: a 
cost-effectiveness analysis. J Clin Oncol. 2015;33(18):2084–91.
 53. Provenzale D, Gupta S, Ahnen DJ, Chen L-M, Chung DC, Cooper 
G, et al. NCCN guidelines. genetic/familial high risk assessment: 
colorectal v1.3019. 2019.
 54. Seifert BA, McGlaughon JL, Jackson SA, Ritter DI, Roberts ME, 
Schmidt RJ, et al. Determining the clinical validity of hereditary 
colorectal cancer and polyposis susceptibility genes using the 
Clinical Genome Resource Clinical Validity Framework. Genet 
Med. 2019;21(7):1507–16.
 55. Lorans M, Dow E, Macrae FA, Winship IM, Buchanan DD. 
Update on hereditary colorectal cancer: improving the clini-
cal utility of multigene panel testing. Clin Colorectal Cancer. 
2018;17(2):e293–305.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
